Showing results (1-10 of 480) with videos related to
Sort By:
Pageof 48
Molecular Cancer Therapeutics|June 1, 2023
Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and BiomarkersBlessie Elizabeth Nelson, Jacob J Adashek, Aakash Akshay Sheth, et al.Med (New York, N.Y.)|March 9, 2023
The abscopal effect in patients with cancer receiving immunotherapyBlessie Elizabeth Nelson, Jacob J Adashek, Steven H Lin, et al.Cancer Medicine|November 22, 2022
On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happeningsBlessie Elizabeth Nelson, Jacob J Adashek, Steven H Lin, et al.Trends in Cancer|October 3, 2020
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision ParadigmJacob J Adashek, Vivek Subbiah, Razelle KurzrockThe Oncologist|July 25, 2019
Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and CoexistJacob J Adashek, Ishwaria M Subbiah, Vivek SubbiahMolecular Cancer Therapeutics|April 12, 2022
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant TumorsJacob J Adashek, Arjun K Menta, Neha K Reddy, et al.NPJ Precision Oncology|May 25, 2023
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastomaBlessie Elizabeth Nelson, Neha K Reddy, Jason T Huse, et al.Cancers|March 22, 2020
Cancer Genetics and Therapeutic Opportunities in Urologic PracticeJacob J Adashek, Alex Leonard, Jason Roszik, et al.Journal of Hematology & Oncology|August 28, 2022
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional responseHanna E Persha, Shumei Kato, Pradip De, et al.Molecular Cancer Therapeutics|September 8, 2021
Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant CancersJacob J Adashek, Aakash P Desai, Alexander Y Andreev-Drakhlin, et al.Pageof 48